Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access ...

Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart ...

The device, bought during Boston Scientific’s acquisition of Silk Road Medical, has a risk of catheter tip separation during ...

Boston Scientific (BSX) stock falls after the company's Q2 2026 results as its Q3 and full-year earnings forecasts trail ...

The trial launch comes as Boston Scientific faces competitive pressures for pulsed-field ablation (PFA) market share.

Confusion over when and if to use the Watchman implant to reduce stroke risks in patients with irregular heartbeats is ...

Boston Scientific’s valuation discount, restructuring plan, earnings profile, and execution risks place its medical ...

Boston Scientific confirmed investors' worst fears Wednesday by cutting 2026 guidance for the second time this year. “This update today is not the outcome we planned or what you have come to expect ...

Boston Scientific cut its full-year outlook after two of its core heart-disease products faced unexpected challenges in the ...

"Second quarter represented a solid quarter for Boston Scientific" (Chairman, President & CEO Michael Mahoney), with total company organic sales growth of 7% and "Q2 adjusted EPS of $0.86" alongside ...

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced publication of a study ...

Boston Scientific BSX is slated to report second-quarter 2026 results on July 29, before the market opens. The Zacks Consensus Estimate for the company’s second-quarter earnings per share (EPS) ...